Covid19, SARS-CoV2 Infection
Conditions
Keywords
respiratory distress, respiratory failure
Brief summary
The primary objective of this study is to provide expanded access of S-nitrosylation therapy for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
Detailed description
Randomized controlled trial for safety of a 6-hour escalating dose of S-nitrosylation therapy or placebo to ventilated patients. This will be a single-site study conducted within the UH-CMC medical ICU designated COVID-19 quarantine areas.
Interventions
DRUGSNO
Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
DRUGNitrogen gas
Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
Sponsors
Case Western Reserve University
James Reynolds
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The investigational product will be prepared and dispensed by designated unblinded site personnel at the pharmacy; the investigational product label will indicate the study number but will not indicate the treatment assignment. Any site personnel involved in the administration and assessment of the investigational product will be blinded to subject treatment assignments throughout the study.
Intervention model description
Single-site, double-blinded, randomized, placebo controlled trial with a superiority design. The study will randomize 24 patients 1:1 (12 treatment vs 12 control) to either S-nitrosylation therapy or placebo arms.
Eligibility
Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
(Severe COVID-19 Status) * Hospitalized with confirmed SARS-CoV-2 infection by polymerase chain reaction (PCR) or other validated tests as they become available within 30 days of enrollment. * In mild respiratory distress, defined as a P/F ratio of between 200 and 325 mm Hg. * Spontaneously breathing subjects receiving \> 4 liters/min of oxygen. * Patients enrolled and able to start ENO treatment after oxygen stabilization. * Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under International Conference on Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (participants ≥ 18 years of age). * 18-89 years of age
Exclusion criteria
* COVID-19 patients with mild to no respiratory distress, defined as P/F ratio \> 325 mm Hg. * COVID-19 patients receiving supplemental oxygen equivalent to an FiO2 of \> 0.90 (reduction of FiO2 at this level or higher when ENO is blended into gas source cannot be avoided). * COVID-19 patients receiving supplemental oxygen with active ventilatory support, CPAP, etc. * Physician of record opposed to enrolling the patient due to perceived safety concerns; or any condition that does not allow the protocol to be followed safely. * Subjects with past medical history of lung malignancy or pneumonectomy or lung transplant * Subjects who have a history of malignancy or other irreversible disease/conditions with a 6-month mortality \> 50% * Subjects that have experienced cardiac arrest with CPR for longer than 30 minutes * Patients on extracorporeal membrane oxygenation (ECMO) + patients intubated on ventilator * Patient groups at an increased risk to form methemoglobin. (e.g. congenital variants of Met-Hb) * Patients with anemia, defined as a hemoglobin of \< 9 g/dL * Individuals who are pregnant or breastfeeding * Individuals with an acute disorder or history of chronic diseases of the heart, lungs, kidney, liver, or any other medical condition that in the opinion of the screening physician makes them unsuitable for study. * Individuals taking nitrates. * Individuals receiving PDE-5 inhibitors, any drugs that are nitric oxide donors (e.g. prilocaine, sodium nitroprusside and nitroglycerine), drugs known to increase methemoglobin (e.g. lidocaine, prilocaine, benzocaine, or dapsone), drugs that interfere with nitrite metabolism (e.g. allopurinol) and drugs that may potentiate hypotension (e.g. antihypertensives, diuretics, meperidine). * Individuals with an inherited or acquired blood coagulation disorder, congenital methemoglobinemia, or a familial hemoglobinopathy that impacts oxygen delivery (e.g. sickle cell). * Individuals who might have difficulty with the placement of a face mask (e.g. claustrophobia, uncontrolled asthma, severe allergies, sensitive skin) and/or the inhalation of a product for approximately 6 hours.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Emergent Adverse Events | 30 days | Adverse events related to SNO therapy. |
| Frequency of Intubation | 30 days | Number of intubations required. |
| Progression to use of ECMO | 30 days | Use of ECMO required. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Hospitalization | 30 days | Duration of total hospitalization days as measured by total hospitalization, ventilator and ICU days |
| All-Cause Mortality | 30, 60 days | All-cause mortality |
| Time to Clinical Status Improvement | 30 days | Number of days required to see a greater than or equal to 2 point improvement on the WHO 9-point clinical status assessment ordinal scale. Clinical status will be assessed using the WHO 9-point ordinal scale as follows: 0\. Uninfected - no clinical or virological evidence of infection 1. Ambulatory - no limitation of activities 2. Ambulatory - Limitation of activities 3. Hospitalized, mild disease - no oxygen therapy 4. Hospitalized, mild disease - oxygen by mask or nasal prongs 5. Hospitalized, severe disease - non-invasive ventilation or high-flow oxygen 6. Hospitalized, severe disease - intubation and mechanical ventilation 7. Hospitalized, severe disease - ventilation + additional organ support (pressors, RRT, ECMO) 8. Dead |
| Discontinuation of Oxygen Therapy | 30 days | Proportion of patients alive and with discontinued oxygen supportive therapy at day 30 |
| Time to Discontinuation of Oxygen Therapy | 30 days | Number of days required to discontinue oxygen supportive therapy |
| Clinical Status | 30 days | Proportion of patients in each stage at maximum severity on the 9-point clinical status assessment ordinal scale. Clinical status will be assessed using the WHO 9-point ordinal scale as follows: 0\. Uninfected - no clinical or virological evidence of infection 1. Ambulatory - no limitation of activities 2. Ambulatory - Limitation of activities 3. Hospitalized, mild disease - no oxygen therapy 4. Hospitalized, mild disease - oxygen by mask or nasal prongs 5. Hospitalized, severe disease - non-invasive ventilation or high-flow oxygen 6. Hospitalized, severe disease - intubation and mechanical ventilation 7. Hospitalized, severe disease - ventilation + additional organ support (pressors, RRT, ECMO) 8. Dead |
| Respiratory Clinical Status | 30 days | Respiratory clinical status assessed by a 7-point respiratory status ordinal scale that captures oxygen requirement, ventilator support or death. 7-Point Respiratory Severity Scale Range: 1-7 Higher values = worse 1. Not receiving oxygen supplementation; AND room air oxygen saturation ≥ 95% 2. Supplemental oxygen ≤ 2 liters/min; OR room air oxygen saturation ≤ 94% 3. Supplemental nasal oxygen \>2 and \<= 5 liters/min 4. Supplemental nasal oxygen \>5 liters/min 5. HFNC or NIV with FiO2 \> 50% 6. Intubation or ECMO 7. Death |
Countries
United States
Outcome results
None listed